196 related articles for article (PubMed ID: 12556562)
1. The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells.
Neri LM; Borgatti P; Tazzari PL; Bortul R; Cappellini A; Tabellini G; Bellacosa A; Capitani S; Martelli AM
Mol Cancer Res; 2003 Jan; 1(3):234-46. PubMed ID: 12556562
[TBL] [Abstract][Full Text] [Related]
2. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
3. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells.
Tabellini G; Cappellini A; Tazzari PL; Falà F; Billi AM; Manzoli L; Cocco L; Martelli AM
J Cell Physiol; 2005 Feb; 202(2):623-34. PubMed ID: 15316930
[TBL] [Abstract][Full Text] [Related]
4. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation.
Bortul R; Tazzari PL; Cappellini A; Tabellini G; Billi AM; Bareggi R; Manzoli L; Cocco L; Martelli AM
Leukemia; 2003 Feb; 17(2):379-89. PubMed ID: 12592338
[TBL] [Abstract][Full Text] [Related]
5. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
6. Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis.
Ishida S; Shigemoto-Mogami Y; Shinozaki Y; Kagechika H; Shudo K; Ozawa S; Sawada J; Ohno Y; Inoue K
Biochem Pharmacol; 2004 Dec; 68(11):2177-86. PubMed ID: 15498508
[TBL] [Abstract][Full Text] [Related]
7. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
[TBL] [Abstract][Full Text] [Related]
8. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
[TBL] [Abstract][Full Text] [Related]
9. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
[TBL] [Abstract][Full Text] [Related]
10. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
11. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
12. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer.
Yuan ZQ; Sun M; Feldman RI; Wang G; Ma X; Jiang C; Coppola D; Nicosia SV; Cheng JQ
Oncogene; 2000 May; 19(19):2324-30. PubMed ID: 10822383
[TBL] [Abstract][Full Text] [Related]
13. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
Chandrasekher G; Sailaja D
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3577-88. PubMed ID: 15452065
[TBL] [Abstract][Full Text] [Related]
15. IGF-I elicits growth of human intestinal smooth muscle cells by activation of PI3K, PDK-1, and p70S6 kinase.
Kuemmerle JF
Am J Physiol Gastrointest Liver Physiol; 2003 Mar; 284(3):G411-22. PubMed ID: 12444011
[TBL] [Abstract][Full Text] [Related]
16. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.
Zhou M; Gu L; Findley HW; Jiang R; Woods WG
Cancer Res; 2003 Oct; 63(19):6357-62. PubMed ID: 14559824
[TBL] [Abstract][Full Text] [Related]
17. PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway.
Wan X; Yokoyama Y; Shinohara A; Takahashi Y; Tamaya T
Cell Death Differ; 2002 Apr; 9(4):414-20. PubMed ID: 11965494
[TBL] [Abstract][Full Text] [Related]
18. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
19. Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation.
Kang YC; Kim KM; Lee KS; Namkoong S; Lee SJ; Han JA; Jeoung D; Ha KS; Kwon YG; Kim YM
Cell Death Differ; 2004 Dec; 11(12):1287-98. PubMed ID: 15297884
[TBL] [Abstract][Full Text] [Related]
20. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]